FDA Clears Mint Patch Pump, But Beta Bionics Slashes 2026 Revenue Outlook
BBNX sits 82% above its 52-week low of $8.8.
Summary
Beta Bionics received FDA clearance for its Mint patch pump, a major regulatory milestone that expands its product line beyond the iLet. However, the company simultaneously cut its 2026 revenue guidance to $121M–$126M from $131M–$136M, citing potential Q4 deferrals ahead of the Mint launch. The full U.S. launch is now targeted for Q1 2027, subject to coverage ramp, with initial pharmacy channel coverage around 40% expected to reach ≥50% in year one. The company also submitted its 3D Intelligence algorithm to the FDA via 510(k), a next-gen dosing feature that could differentiate its AID platform. This follows strong Q2 results reported in July, but the guidance cut signals near-term disruption as the company transitions to the new product. Investors will focus on the pace of payer coverage and early adoption metrics once Mint launches.
At the time of this announcement, BBNX was trading at $15.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $745.5M. The 52-week trading range was $8.80 to $32.71. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.